Rigel (RIGL) board member receives 5,750 RSUs in equity grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Wasman Jane reported acquisition or exercise transactions in this Form 4 filing.

RIGEL PHARMACEUTICALS INC director Jane Wasman received an equity grant of 5,750 shares of Common Stock. The award is structured as Restricted Stock Units that will fully vest on the date prior to the company’s next Annual Meeting, as long as she continues serving on the Board of Directors.

Following this grant, her direct holdings increase to 18,250 shares, reflecting routine, compensation-related equity rather than an open-market stock purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Wasman Jane

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,750	$0.00	--

Holdings After Transaction: Common Stock — 18,250 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares granted: 5,750 shares Grant price per share: $0.00 per share Shares held after grant: 18,250 shares +1 more

4 metrics

Shares granted 5,750 shares Restricted Stock Unit award on May 15, 2026

Grant price per share $0.00 per share Equity compensation award, not open-market purchase

Shares held after grant 18,250 shares Total direct holdings following the reported transaction

Vesting condition Fully vests before next Annual Meeting Requires continuous service on Board of Directors

Key Terms

Restricted Stock Unit, Annual Meeting, Board of Directors

3 terms

Restricted Stock Unit financial

"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Annual Meeting financial

"The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service..."

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

Board of Directors financial

"...subject to the Reporting Person's continuous service on the Company's Board of Directors."

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

Form 4 Insider Transactions: What Each Field Means →

05/19/2026 - 08:50 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wasman Jane

(Last)

(First)

(Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/15/2026		A		5,750⁽¹⁾	A	$0	18,250	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

	/s/ Raymond Furey (Attorney-in-Fact)	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Rigel (RIGL) director Jane Wasman report in this Form 4?

Director Jane Wasman reported receiving 5,750 shares of Common Stock as a Restricted Stock Unit award. The equity grant is compensation for board service, not an open-market purchase, and increases her direct holdings to 18,250 shares after the transaction.

How many Rigel (RIGL) shares were granted to Jane Wasman and at what price?

Jane Wasman was granted 5,750 shares of Common Stock at a reported price of $0.00 per share. This reflects a compensation-related equity award, consistent with typical director pay practices, rather than a cash purchase made in the open market.

When do Jane Wasman’s Rigel (RIGL) Restricted Stock Units fully vest?

The Restricted Stock Units fully vest on the date prior to Rigel’s next Annual Meeting. Vesting is conditioned on her continuous service on the company’s Board of Directors through that date, aligning the award with ongoing governance responsibilities.

How many Rigel (RIGL) shares does Jane Wasman own after this award?

After the 5,750-share award, Jane Wasman’s direct holdings total 18,250 shares of Common Stock. This figure reflects her position following the reported grant and provides context for the relative size of this compensation grant versus her overall stake.

Is Jane Wasman’s Rigel (RIGL) Form 4 transaction a buy or a grant?

The Form 4 shows a grant, coded “A” for grant, award, or other acquisition, not an open-market buy. The 5,750 shares are to be acquired through Restricted Stock Units that vest over time, subject to her continued board service at Rigel Pharmaceuticals.